512 — Grand Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- HK$23.74bn
- HK$27.06bn
- HK$11.64bn
Annual income statement for Grand Pharmaceutical, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8,598 | 9,562 | 10,530 | 11,645 | 12,283 |
| Cost of Revenue | |||||
| Gross Profit | 5,247 | 5,951 | 6,524 | 6,738 | 6,780 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5,833 | 6,864 | 7,955 | 8,761 | 10,703 |
| Operating Profit | 2,765 | 2,698 | 2,574 | 2,884 | 1,580 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 2,786 | 2,517 | 2,344 | 2,852 | 1,494 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2,405 | 2,098 | 1,895 | 2,466 | 1,244 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 2,403 | 2,079 | 1,880 | 2,468 | 1,241 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2,403 | 2,079 | 1,880 | 2,468 | 1,241 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.685 | 0.598 | 0.638 | 0.704 | 0.364 |
| Dividends per Share |